BMRA Stock Overview
Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Biomerica, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.71 |
| 52 Week High | US$2.13 |
| 52 Week Low | US$0.67 |
| Beta | -1.04 |
| 1 Month Change | -18.07% |
| 3 Month Change | -22.50% |
| 1 Year Change | -42.50% |
| 3 Year Change | -85.05% |
| 5 Year Change | -69.53% |
| Change since IPO | -93.66% |
Recent News & Updates
Recent updates
Is Biomerica (NASDAQ:BMRA) In A Good Position To Deliver On Growth Plans?
Dec 20
Here's Why We're Watching Biomerica's (NASDAQ:BMRA) Cash Burn Situation
Aug 31We're Keeping An Eye On Biomerica's (NASDAQ:BMRA) Cash Burn Rate
Mar 04Amazon starts selling Biomerica's Aware Breast Self Exam device, EZ Detect test
Sep 29Biomerica: One To Watch Closely For The Future, But From The Sidelines For Now
Sep 09Biomerica reports FY results
Aug 29Biomerica stock jumps after Walmart to begin selling co's Aware Breast Self Exam device
Jul 14Most Shareholders Will Probably Find That The CEO Compensation For Biomerica, Inc. (NASDAQ:BMRA) Is Reasonable
Dec 03Biomerica (NASDAQ:BMRA) Is In A Good Position To Deliver On Growth Plans
Dec 02Is Biomerica Stock A Buy Or Sell After Q4 Earnings? Catalysts To Watch Into 2022
Sep 15Biomerica (BMRA) Investor Presentation - Slideshow
Jun 14Companies Like Biomerica (NASDAQ:BMRA) Are In A Position To Invest In Growth
Jun 13Biomerica, Inc.'s (NASDAQ:BMRA) Profit Outlook
Apr 04Should You Review Recent Insider Transactions At Biomerica, Inc. (NASDAQ:BMRA)?
Mar 08Companies Like Biomerica (NASDAQ:BMRA) Are In A Position To Invest In Growth
Feb 10The Biomerica (NASDAQ:BMRA) Share Price Has Soared 405%, Delighting Many Shareholders
Jan 15
Biomerica soars as its COVID-19 antigen test wins European nod
Jan 12When Will Biomerica, Inc. (NASDAQ:BMRA) Become Profitable?
Dec 20Biomerica clinical trial for IBS nears enrollment completion
Dec 09How Much Does Biomerica's (NASDAQ:BMRA) CEO Make?
Nov 23Shareholder Returns
| BMRA | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -5.1% | 1.8% | 1.2% |
| 1Y | -42.5% | -0.5% | 24.9% |
Return vs Industry: BMRA underperformed the US Medical Equipment industry which returned -0.7% over the past year.
Return vs Market: BMRA underperformed the US Market which returned 24.7% over the past year.
Price Volatility
| BMRA volatility | |
|---|---|
| BMRA Average Weekly Movement | 9.4% |
| Medical Equipment Industry Average Movement | 7.2% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: BMRA's share price has been volatile over the past 3 months.
Volatility Over Time: BMRA's weekly volatility has decreased from 15% to 9% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1971 | 62 | Zack Irani | www.biomerica.com |
Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company’s diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances, and other medical complications; or to measure bacteria, hormones, antibodies, antigens, or other substances which may exist in the human body, stools, or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories.
Biomerica, Inc. Fundamentals Summary
| BMRA fundamental statistics | |
|---|---|
| Market cap | US$12.15m |
| Earnings (TTM) | -US$6.35m |
| Revenue (TTM) | US$5.41m |
2.2x
P/S Ratio-1.9x
P/E RatioIs BMRA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BMRA income statement (TTM) | |
|---|---|
| Revenue | US$5.41m |
| Cost of Revenue | US$4.79m |
| Gross Profit | US$620.00k |
| Other Expenses | US$6.97m |
| Earnings | -US$6.35m |
Last Reported Earnings
Feb 29, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.38 |
| Gross Margin | 11.47% |
| Net Profit Margin | -117.42% |
| Debt/Equity Ratio | 0% |
How did BMRA perform over the long term?
See historical performance and comparison